Management of Hypertension With a Fixed-Dose (Single-Pill) Combination of Bisoprolol and Amlodipine

详细信息    查看全文

• 作者：Ulrike Gottwald-Hostalek ; Ningling Sun ; Christian Barho and Steven Hildemann
• 刊名：Clinical Pharmacology in Drug Development
• 出版年：2017
• 出版时间：January/February 2017
• 年：2017
• 卷：6
• 期：1
• 页码：9-18
• 全文大小：135K
• ISSN：2160-7648

文摘

Hypertension is currently one of the greatest global health care challenges. Although many effective drugs are available, combinations of 2 or more medications are often required to meet clinical targets. Combination therapy has several advantages over monotherapy: lower doses of each drug can be used to achieve therapeutic goals; lower doses may lead to fewer adverse events, facilitating patient adherence; and using multiple drugs with different modes of action may be more effective in treating multifactorial diseases, including hypertension. Adherence is an important consideration when requiring patients to self-administer multiple medications; as the number of concurrent medications increases, patient adherence tends to decrease. Recent evidence suggests that fixed-dose combinations (FDCs) may be more effective than free-dose combinations, as they provide all necessary medications in a single convenient tablet/single-pill combination. Among combinations of hypertension medications, a β-blocker such as bisoprolol with a calcium channel blocker such as amlodipine is an effective combination therapy for hypertension, with distinct and complimentary modes of action. With advantages over free-dose combinations, the FDC of bisoprolol/amlodipine is thus an effective and convenient treatment for hypertension, allowing more patients to achieve their therapeutic goals, while potentially reducing the burden of hypertension on health care systems.